

# Olivier Theisen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9373259/publications.pdf>

Version: 2024-02-01

16  
papers

86  
citations

1684188

5  
h-index

1474206

9  
g-index

17  
all docs

17  
docs citations

17  
times ranked

219  
citing authors

#	ARTICLE	IF	CITATIONS
1	Lineage switch and relapse in sanctuary site: Some lessons to learn about plasticity in acute leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29683.	1.5	0
2	Fluctuating plasmacytosis in an immunocompetent woman leading a diagnosis of plasmablastic lymphoma. <i>Annals of Hematology</i> , 2021, 100, 285-287.	1.8	1
3	No survival improvement in patients with high-risk multiple myeloma harbouring del(17p) and/or t(4;14) over the two past decades. <i>British Journal of Haematology</i> , 2021, 194, 635-638.	2.5	7
4	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. <i>Haematologica</i> , 2021, 106, 701-707.	3.5	10
5	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2021, 138, 3465-3465.	1.4	0
6	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group. <i>Hematological Oncology</i> , 2020, 38, 446-455.	1.7	5
7	Flow cytometry in the diagnosis of mature B-cell lymphoproliferative disorders. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 113-120.	1.3	11
8	Survival Trends over 18 Years of Patients with Multiple Myeloma Harboring Del(17p) and/or t(4;14): A Retrospective Real-World Study. <i>Blood</i> , 2020, 136, 15-17.	1.4	0
9	A New Cytokine-Based Stratification Is Highly Predictive of Survivals in AML Patients. <i>Blood</i> , 2019, 134, 1412-1412.	1.4	0
10	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. <i>Blood</i> , 2019, 134, 5771-5771.	1.4	0
11	A blueberry muffin rash at birth. <i>British Journal of Haematology</i> , 2018, 182, 168-168.	2.5	1
12	CD200 expression in flow cytometry helps to distinguish mantle cell lymphoma from other CD5-positive B-cell neoplasms. <i>Hematological Oncology</i> , 2018, 36, 607-609.	1.7	7
13	Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide. <i>Haematologica</i> , 2018, 103, e143-e146.	3.5	41
14	Poor Prognosis Associated with Gains of CCND1 in Mantle Cell Lymphoma Treated By First Line Immuno-Chemotherapy – a Study By the Lysa Group. <i>Blood</i> , 2018, 132, 4099-4099.	1.4	0
15	Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study. <i>Blood</i> , 2018, 132, 1484-1484.	1.4	0
16	Interest of the XN-10 Analyzer to Screen for Myelodysplastic Syndromes on Complete Blood Count (CBC) Especially with Hemoglobin Levels and Neut-WX. <i>Blood</i> , 2016, 128, 5518-5518.	1.4	3